Advertisement

Chemotherapy of Malignant Lymphomas

  • A. Stacher
Part of the Acta Neuropathologica book series (NEUROPATHOLOGIC, volume 6)

Summary

In malignant lymphomas generally, radiotherapy is the treatment of choice. Chemotherapy cannot be very effective in lymphomas of the CNS because most of the cytostatic drugs in question are not able to pass the blood-brain barrier. But in cases in which malignant lymphomas are disseminated throughout the body including the CNS, cytostatic chemotherapy is the only means of prolonging the life of the patient. In such cases one has to distinguish between Hodgkin’s disease and non-Hodgkin lymphomas. Alkylating agents, metaphase inhibitors and antibiotics are used in the treatment of malignant lymphomas. The best results are achiev. d. with combination schedules. In Hodgkin lymphomas the so-called MOPP-schedule is the most effective. In non-Hodgkin lymphomas the same drugs are usually given without procarbacine. After having achiev. d. a remission, maintenance therapy is very important. Vinblastine and Chlorambuzil are able to prolonge the remission. When resistance to these drugs occurs Bleomycin, Adriamycin, CCNU and Peptichemio are effective agents. The results as well as the side effects of such regimens are described.

Key words

Chemotherapy Malignant Lymphomas Induction Therapy Maintenance Therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    de Lena, M., Monfardini, S., Bonadonna, G.: Intensive combination chemotherapy in malignant lymphomas. In A. Stacher (ed.): Leukämien und maligne Lymphome. München, Berlin, Wien: Urban & Schwarzenberg 1973.Google Scholar
  2. 2.
    de Vita, V.T., Carbone, P.T.: Chemotherapeutic implications of staging in Hodgkin’s disease. Cancer Res. 31, 1838 (1971).Google Scholar
  3. 3.
    de Vita, V.T., Serpick, A.A., Carbone, P.T.: Combination chemotherapy in advanced Hodgkin’s disease. Am. Int. Med. 73, 881 (1970).CrossRefGoogle Scholar
  4. 4.
    Fischer, M., Mitrou, P.S., Schubert, J.C.F., Martin, H., Hübner, K.: Zur Therapie des Morbus Hodgkin. Gegenüberstellung der Ergebnisse mit dem De Vita-Programm und verschiedenen Zweifach-Kombinationen in Abhängigkeit vom histologischen Typ. In A. Stacher (ed.): Leukämien und maligne Lymphome. München, Berlin, Wien: Urban & Schwarzenberg 1973.Google Scholar
  5. 5.
    Frei, E.: Recent advances in the management of lymphoma. 1st Meeting Europ. Div. Internat. Soc. Hemat., Milano, 1971. Abstract nr. 284.Google Scholar
  6. 6.
    Kimura, K., Sakai, Y., Konda, C., Shimoyama, M., Sakano, T., Kitahara, T., Mikuni, M.: Chemotherapy of malignant lymphoma with special references to the effects of Bleomycin and sequential therapy of Bleomycin and Vincaalkaloids. In A. Stacher (ed.): Leukämien and maligne Lymphome. München, Berlin, Wien: Urban & Schwarzenberg 1973.Google Scholar
  7. 7.
    Klein, H.O., Lennartz, K.J., Gross, R.: Partielle Synchronisation der Tumor-zellproliferation and zellphasenspezifisches “Timing” der Zytostatikagabe. Erste klinische Ergebnisse bei lymphoretikulären Tumoren, akuter Leukosen sowie Bronchialkarzinomen. In A. Stacher (ed.): Leukämien und maligne Lymphome. München, Berlin, Wien: Urban & Schwarzenberg 1973.Google Scholar
  8. 8.
    Lennert, K.: Morphology and classification of lymphomas and so-called reticuloses. Acta Neuropath. Suppl. VI, 1–16 (1975).Google Scholar
  9. 9.
    Lukes, R.J., Craver, L.F., Hall, T.C., Rappaport, H., Rubin, P.: Report of the nomenclature committee. Cancer Res. 26, 1311, (1966).Google Scholar
  10. 10.
    Stacher, A.: Grundsätze der Therapie des Morbus Hodgkin und der übrigen malignen Lymphome. In A. Stacher (ed.): Leukümien und maligne Lymphome. München, Berlin, Wien: Urban & Schwarzenberg 1973.Google Scholar
  11. 11.
    Trepel F.: Zellproliferation in malignen Lymphomen. In A. Stacher (ed.): Leukämien und maligne Lymphome. München, Berlin, Wien: Urban & Schwarzenberg 1973.Google Scholar
  12. 12.
    Medical News (Leading article): DMP-once discarted for toxicity-combats meningeal leukemia. J. amer. Med. Ass. 224, 1079 (1973).CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1975

Authors and Affiliations

  • A. Stacher
    • 1
  1. 1.1st Medical DepartmentLudwig Boltzmann-Institute for Leukemia Research and Hematology, Hanusch-KrankenhausViennaAustria

Personalised recommendations